

Special Issue

Extracellular Vesicles and Bionanovesicles in Cell-Free Therapies and Drug delivery

Message from the Guest Editors

Extracellular vesicles (EVs: exosomes, microvesicles) are the membrane vesicles released by most types of cells. Bionanovesicles (exosome mimetics/nanovesicles) are engineered vesicles from cells. Recent studies show that EVs/mimetics/nanovesicles that are derived/engineered from cells have different functions and therapeutic effects. Numerous studies reported that these EVs and bionanovesicles can efficiently deliver many different kinds of cargo to the target cell. Therefore, they are often used to deliver therapeutic cargo for treatment. Therapeutics, such as small molecules or nucleic acid drugs, can be incorporated into exosomes and then delivered to specific types of cells or tissues to realize targeted drug delivery. EVs and bionanovesicles hold promise for cell-free therapies and drug delivery for a wide range of diseases.

We cordially invite you to present your excellent EV- or bionanovesicles-based therapies and drug delivery research discoveries to this Special Issue, for the wider scientific and academic community.

Guest Editors

Dr. Ramya Lakshmi Rajendran

Department Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea

Dr. Prakash Gangadaran

Department of Biomedical Science & Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea

Deadline for manuscript submissions

closed (30 December 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/92245

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)